Jaideep Dhariwal

Guy's And St Thomas' NHS Trust
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Identifying the residual unmet need in severe asthma.

Identifying the residual unmet need in severe asthma.

Journal: The Lancet. Respiratory medicine

Published: May 29, 2026

Application of T2 Biomarkers to Support Steroid Stewardship in Severe Asthma - a retrospective cohort study.

Application of T2 Biomarkers to Support Steroid Stewardship in Severe Asthma - a retrospective cohort study.

Journal: The journal of allergy and clinical immunology. In practice

Published: January 06, 2026

Application of T2 biomarkers to support steroid stewardship in severe asthma-a retrospective cohort study.

Application of T2 biomarkers to support steroid stewardship in severe asthma-a retrospective cohort study.

Journal: The journal of allergy and clinical immunology. In practice

Published: January 06, 2026

Adherence to Inhaled Corticosteroids and Clinical Outcomes Following a Year of Tezepelumab Therapy for Severe Asthma.

Adherence to Inhaled Corticosteroids and Clinical Outcomes Following a Year of Tezepelumab Therapy for Severe Asthma.

Journal: The journal of allergy and clinical immunology. In practice

Published: June 05, 2025

Fractional exhaled nitric oxide as a novel biomarker of relapse in eosinophilic granulomatosis with polyangiitis.

Fractional exhaled nitric oxide as a novel biomarker of relapse in eosinophilic granulomatosis with polyangiitis.

Journal: American journal of respiratory and critical care medicine

Published: May 26, 2025

Tezepelumab in Patients With Eosinophilic Granulomatosis With Polyangiitis After Suboptimal Response to Anti-IL-5/5R Therapy.

Tezepelumab in Patients With Eosinophilic Granulomatosis With Polyangiitis After Suboptimal Response to Anti-IL-5/5R Therapy.

Journal: Chest

Published: May 06, 2025

Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma.

Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma.

Journal: Allergy

Published: February 20, 2025

Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two-Year Real-World Data With Benralizumab.

Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two-Year Real-World Data With Benralizumab.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: April 17, 2024

Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5/5R Therapy in Severe Eosinophilic Asthma.

Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5/5R Therapy in Severe Eosinophilic Asthma.

Journal: The journal of allergy and clinical immunology. In practice

Published: January 02, 2024

Detection of Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis (EGPA) With Multiparametric Cardiovascular Magnetic Resonance (CMR).

Detection of Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis (EGPA) With Multiparametric Cardiovascular Magnetic Resonance (CMR).

Journal: JACC. Cardiovascular imaging

Published: November 13, 2023

Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.

Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.

Journal: The journal of allergy and clinical immunology. In practice

Published: October 24, 2023

The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma.

The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma.

Journal: The European respiratory journal

Published: February 20, 2023

Showing 1-12 of 39

Last Updated: 09/26/2026